Amgen
AstraZeneca, with its biologics arm MedImmune, entered into a global collaboration with Amgen in April 2012 to co-develop and commercialize five monoclonal antibodies from Amgen’s clinical portfolio across a range of inflammatory indications. The number of molecules and indications involved make it one of the biggest peer-to-peer deals ever completed within the industry and sets a benchmark for other companies pursuing similar deal structures.
Bristol-Myers Squibb
Further to Bristol-Myers Squibb acquisition of Amylin Pharmaceuticals in August 2012, our existing collaboration with Bristol-Myers Squibb was expanded to include the development and commercialisation of Amylin’s portfolio of diabetes products. The addition of these products strengthens our worldwide diabetes alliance, creating a broader disease management platform for patients, physicians and payers.
Other featured case studies
Hutchison Medi Pharma
Hutchison Medi Pharma
We entered into a global licensing, co-development, and commercialisation agreement for Volitinib (HMPL-504) with Hutchison Medi Pharma in December 2011.
Deal type:
Global collaboration, co-development and commercialisation
Rigel Pharmaceuticals
Rigel Pharmaceuticals
We entered into a worldwide licence agreement with Rigel Pharmaceuticals for Fostamatinib disodium for the treatment of Rheumatoid Arthritis (RA) in February 2010.
Deal type:
Worldwide licence agreement